About us

Our international and diverse Drug Discovery Chemistry team has more than 180 years of pharmaceutical R&D experience.

Collectively as a team, we worked on more than 100 biomolecular targets from all major gene families and across all main therapeutic areas, such as oncology, neuroscience, cardiovascular & metabolic diseases, inflammation, autoimmune disorders as well as genetic & rare diseases. We have extensive experience in small molecule & peptide therapeutics, as well as siRNA conjugates for targeted delivery.

At Taros, we are running our own state-of-the-art Drug Discovery Chemistry facilities in Germany with the option for process research chemistry, upscaling & kilolab production in our own Chemistry facilities in India. Biological in vitro and in vivo compound profiling is routinely outsourced to established and trusted partners.

Products and services

Our broad and deep expertise includes:

  • Pharmaceutical R&D
  • Drug Discovery & Medicinal Chemistry
  • Computational Chemistry & Molecular Modeling
  • Library Design & Production
  • Process Research & Kilolab Production (non GMP)

We are also proud to lead and coordinate the Discovery Chemistry consortium of the European Lead Factory (ELF), an IMI-funded Horizon 2020 project with € 196 million and 30 partners, as well as being a distinguished member of the Drug Discovery Hub Dortmund (DDHD), funded with € 11 million over a 3-year-period.

We are agnostic to any type of collaboration in Drug Discovery, from FTE-based work all the way up to fully integrated Drug Discovery projects.

Taros Chemicals
Emil-Figge-Str. 76a
44227 Dortmund

Phone: +49 231 97427211
Fax: +49 231 97427219
Internet: www.taros.de
E-mail: Send message

Contact person

Thorsten Genski
Senior Medicinal Chemist
Phone: +49 231 97427227
E-mail: Send message

News & Innovations

Dortmund Alliance Receives 11 Million Euros for the Development of New Lead Compounds

Dortmund, 01.05.2018 ++++

Drug Discovery Hub Dortmund (DDHD) is the name of the new initiative at the Zentrum für integrierte Wirkstoffforschung (ZIW) of the TU Dortmund University (TU), which got started on 1 April 2018. Scientists from eight institutions combine their manifold expertise to develop an infrastructure for drug discovery in North Rhine-Westphalia. In addition to the TU Dortmund, the Max-Planck-Institute for Molecular Physiology (MPI), the Leibniz Research Centre for Working Environment and Human Factors (IfADo), the Leibniz-Institut für Analytische Wissenschaften - ISAS - e.V., the Taros GmbH & Co. KG, the PROvendis GmbH, the BioMedizinZentrum Dortmund (BMZ), and the Lead Discovery Center GmbH (LDC) are participating.

The project has a total volume of 11 million euros over a 3-year-period. It is funded in the scope of the Forschungsinfrastrukturen NRW Program (NRW research infrastructures) of the state of North Rhine-Westphalia with funds from the European Fund for Regional Development (EFRE). The DDHD is to bridge the critical innovation gap between basic academic research and industrial application. Since the process of drug discovery is extremely complex, it requires an interdisciplinary cooperation of many different scientific specialist fields. Thus, the eight partners form a unique and well-proven network at the Dortmund site.

The DDHD acts as an incubator for drug discovery projects throughout North Rhine-Westphalia. In cooperation with the patent marketing organisation PROvendis, results of excellent basic drug discovery are to be translated into economic projects. Innovative findings made in basic academic research are to be transformed into lead substances compatible with industrial expectations, which specifically means that compounds are multiparametric optimised so that they fully comply with the high pharmaceutical standards. The molecular lead compounds will be available for further in depth scientific studies. In case of success, the projects are then transferred to the pharmaceutical industry and developed to marketability. Alternatively, individual projects may be transferred to spin-offs for further development. The source for such drug discovery projects are the universities and academic institutions of North Rhine-Westphalia.

“We are very pleased about the funding which enables the building of a unique infrastructure and the implementation of innovative projects“, states Prof. Daniel Rauh, DDHD Coordinator and Professor for Chemical Biology and Medicinal Chemistry at the TU Dortmund University. “In its capacity as an integrative initiative, the DDHD represents the scientific competence area of “Biomedicine and Drug Discovery” of the Dortmund Science Masterplan. It plays an important role in the strengthening of Dortmund as a biotechnology location and as an innovation center in North Rhine-Westphalia. Together with complementing projects, such as „Medicinal Chemistry in Dortmund“, funded by the Federal Ministry for Education and Research, the DDHD emphasises the national importance of Dortmund as a location for early-stage drug discovery.”

Further reading
Taros Appoints Torsten Hoffmann as Senior Vice President Drug Discovery

Dortmund, October 1, 2018 ++++

Taros Chemicals GmbH & Co. KG today announced the appointment of Dr Torsten Hoffmann as Senior Vice President Drug Discovery, effective October 1st, 2018. In his role, Torsten will further strengthen and accelerate Taros’ continued growth of its drug discovery business.

With more than 20 years of international R&D leadership experience, Torsten is an expert in the field of Drug Discovery. For the past 5 years he has served as Chief Operating Officer and Chief Scientific Officer at Silence Therapeutics Plc, as Chief Scientific Officer and Managing Director at Proteros biostructures GmbH, and prior to that as Chief Scientific Officer and Executive Vice President at Zealand Pharma A/S. During this tenure and under his leadership, he has been instrumental in building and growing the proprietary R&D portfolios of these biotech companies with the most advanced assets now being developed in clinical phase 3 trials.

Torsten started his career at Roche where he spent 16 years in various roles with increasing responsibility including Site Head of Medicinal Chemistry in Basel, and Head of the Global Roche Postdoc Fellowship Program. Under his leadership, his group created 52 new chemical lead series and more than 25 NCEs entered clinical trials as potential Roche medicines. Moreover, he is the lead inventor of the anti-emetic medicine Netupitant, discovered at Roche and approved by the FDA as Akynzeo© in 2014.

Commenting on the appointment, Dr Dimitrios Tzalis, Founder & CEO said:

“We are very delighted that Torsten has joined Taros at this pivotal time for the company. As we continue to develop our drug discovery business, Torsten will add extensive industrial sector experience as well as an outstanding track record in medicinal chemistry and drug discovery collaborations. I am confident this will not o nly boost our own efforts, indeed the whole Drug Discovery Hub in Dortmund will benefit from his experience. I am very much looking forward to collaborating with Torsten as he will participate in shaping the future of Taros regarding integrated drug discovery and proprietary technologies.”

Dr Torsten Hoffmann added:

"These are exciting times for Taros currently providing expertise and tangible results to its partners through drug discovery campaigns in various therapeutic areas. In addition, building on the enormous potential, created during the EUR 196 million funded European Lead Factory (ELF), will be an excellent opportunity to further accelerate Taros’ expansion into Drug Discovery. It will be my great pleasure working with this enthusiastic team in Dortmund as well as connecting to the inspiring network of highly talented scientists within the entire Drug Discovery cluster."

Further reading
CARDIOREG alliance: ZeClinics and Taros to develop new heart regeneration therapies

Barcelona, Spain & Dortmund, Germany, 30. January 2019 ++++

ZeClinics SL, a biotech firm focused on preclinical services with zebrafish, announced today that they have entered into a joint research agreement with Taros Chemicals GmbH, a company specializing in drug discovery and medicinal chemistry research, to develop novel therapies for the treatment of ischemic heart disease.

“We are thrilled that Taros has joined our efforts to identify therapeutic targets promoting heart regeneration after ischemic injury. Their extensive knowledge in drug discovery including computer-aided drug design will prove pivotal in identifying hit and lead compounds,” said Dr. Simone Calzolari, chief commercial officer at ZeClinics. “Ischemic heart disease represents the leading cause of death worldwide, so any progress made in cardiac regeneration therapies could literally benefit millions of people everywhere".

Taros Chemicals will be responsible for hit generation and optimization, the chemical part of the project, involving in silico screening as well as chemical synthesis of the hit candidate compounds in sufficient amounts to allow disease-specific profiling. ZeClinics in turn will evaluate the pro-regenerative function of candidate genes, the biological part of the project, through the development of zebrafish transgenic models and the in vivo characterization of relevant cardiovascular parameters with their ZeCardio software platform. The unique combination of cutting-edge methodologies and analytical proficiency from both companies will streamline the discovery of heart regeneration biomarkers and lead molecules.

“Cardiac regeneration can effectively compensate the loss of cardiac muscle after ischemic injury but molecular mechanisms enabling it are dormant in humans,” said Dr. Torsten Hoffmann, Senior Vice President Drug Discovery at Taros. “Fortunately, zebrafish cardiomyocytes have preserved the ability to proliferate after infarction, so by sharing ZeClinics’ expertise in zebrafish and CRISPR genome editing we have an exciting opportunity to discover and design new molecules promoting heart functional recovery upon ischemia.”

This ambitious CARDIOREG program falls under the German-Catalonian Joint Research and Development Project, an international partnership framework between Germany and Catalonia (Spain) aimed to promote the development of innovative products, technology-based services or methods in application areas with a strong market potential. The project, which will span a three-year period, will be overseen by the German Federal Ministry for Economic Affairs and Energy (BMWi), the Catalan Agency for Competitiveness of the Catalan Ministry of Industry (ACCIÓ) and management agency AiF Projekt GmbH.

Further reading

Click here if you notice an image that violates copyright or privacy rights.

Get in contact

We use cookies and the web analysis tool Matomo in order to optimally design and continuously improve our website for you. By continuing to use our website, you agree to this. Further information and an objection possibility can be found here: Data protection